Responses
Poster Presentation
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model
Compose a Response to This Article
Other responses
No responses have been published for this article.
